This report outlines the recommendations issued by the National Institutes of Health (NIH) Late Effects Consensus Conference, which was tasked with planning the next phase of hematopoietic cell transplantation (HCT) research “to ensure that no survivor is left behind.”
The table below highlights key recommendations from the consensus report.
|Area of research||Selected recommendations based on post-HCT risks|
|Cardiac, vascular and metabolic||HCT survivors have approximately 4 times the risk of developing cardiovascular risk than the general population.
|Subsequent neoplasms||Subsequent solid tumor neoplasms occur at more than a two-fold risk in HCT survivors compared to the general population, with a high incidence in skin malignancies.
|Immune dysregulation||There is a growing awareness of very late lethal infections in the absence of active GVHD.
|Quality of life and psychosocial outcomes||HCT recipients are at a long-term risk for psychological distress that can affect survival.
|Research methodology and study design||To better understand post-transplant late effects, there is a critical need to establish new cohorts or expand existing cohorts that capture comprehensive and complete follow-up of HCT recipients.
|Health care delivery||HCT survivor care needs to be responsive to the preferences of the patient and caregivers with close coordination between the referring physician and transplant center staff.
Health care delivery models